Home

Moderate to Severe Plaque Psoriasis

Cimzia demonstrates durable efficacy through pooled data from the Cimzia arms of the CIMPASI 1 and CIMPASI 2 trials.2

Scroll or click the links to jump to any section below:
Off
Did you know?

Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1

Click here for full details

Off

Efficacy

Off

Safety profile

Off

Dosing

Off

Unique molecular structure

Off

Women of childbearing age

Reducing the treatment burden for women of childbearing age

Due to the emerging biosimilar market, trusts are being encouraged to use the best value biologic as the first line option.13 In addition to financial costs, it is important to consider the wider impact on the patient, their family and the NHS when a patient is on a treatment journey e.g. switching treatments, repeated hospital visits, loss of work days.14

Off

References

  1. Cimzia® Summary of Product Characteristics. [Accessed April 2021].
  2. Gordon, K et al. 2020. British Journal of Dermatology, DOI 10.1111/bjd.19393.
  3. Enbrel® Summary of Product Characteristics. [Accessed April 2021].
  4. Remicade® Summary of Product Characteristics. [Accessed April 2021].
  5. Humira® Summary of Product Characteristics. [Accessed April 2021].
  6. Cosentyx® Summary of Product Characteristics. [Accessed April 2021].
  7. Taltz® Summary of Product Characteristics. [Accessed April 2021].
  8. Simponi® Summary of Product Characteristics. [Accessed April 2021].
  9. Weir N, et al. Therapy. 2006;3(4):535–545.
  10. Furst D. Clin Exp Rheumatol. 2010;28(3 Suppl 59):S5–12.
  11. Porter C, et al. J Reprod Immunol. 2016;116:7–12.
  12. Roopenian D, et al. Nat Rev Immunol. 2007;7(9):715–725.
  13. NHS England 2017 Commissioning framework for biological medicines (including biosimilar medicines) https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf [Accessed April 2021]
  14. NHS RightCare Musculoskeletal (MSK) Workstream
    https://www.england.nhs.uk/rightcare/workstreams/musculoskeletal-msk/ [Accessed April 2021]
Off
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: June 2021
IE-P-CZ-AS-2100053